# Siolta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/siolta-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.sioltatherapeutics.com
- Total disclosed funding: $42M
- Latest round: Series C (Mar 12, 2024)
- Investors on record: 6

## About

Based in California, US, and founded in 2016 by CEO Nikole Kimes, Siolta Therapeutics, Inc. operates as a developer of microbiome therapeutics combined with bacteria, fungi, protozoa, and viruses that lives inside the human body to treat and prevent inflammatory diseases. In March 2024, Siolta Therapeutics, Inc. raised USD 12 million in Series C funding co-led by Capital Management and Khosla Ventures, with participation from Seventure, Global Brain, Time Ventures, and National Institute of Allergy and Infectious Diseases. 

Siolta Therapeutics, Inc. developed live biotherapeutics and molecular diagnostic tools to target the core drivers of diseases particularly within the maternal-infant axis. It leverages advanced microbial science, clinical data, and bioinformatics to create targeted therapies. The company’s products are designed to reestablish a healthy gut microbiome using naturally occurring bacteria and are focused to prevent and treat a variety of diseases, including atopic conditions and other disorders associated with microbiome dysbiosis. 

The company plans to use the funding from March 2024 to support the further clinical development of Siolta’s lead product, STMC-103H, a defined-consortia Live Biotherapeutic Product (LBP) focused on preventing the onset of atopic diseases in newborns.

## Funding rounds

- Series C, Mar 12, 2024, $12M — Seventure Partners, Khosla Ventures, Global Brain, National Institute of Allergy and Infectious Diseases, Time Ventures, SymBiosis Capital Management
- Series B, Sep 22, 2020, $30M — Seventure Partners, Khosla Ventures, Global Brain, SymBiosis Capital Management

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B, Series C
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B, Series C
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series B, Series C
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B, Series C
- National Institute of Allergy and Infectious Diseases — Series C
- Time Ventures (https://capitalatlas.ai/funds/time-ventures) — Series C